Wells Fargo & Company Increases Envista (NYSE:NVST) Price Target to $21.00

Envista (NYSE:NVST) had its price objective upped by analysts at Wells Fargo & Company from $20.00 to $21.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price target points to a potential downside of 1.25% from the company’s current price.

NVST has been the subject of several other research reports. Morgan Stanley lifted their price target on Envista from $19.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Thursday. Leerink Partnrs upgraded Envista from a “strong sell” rating to a “hold” rating in a report on Thursday, October 31st. Piper Sandler increased their price target on Envista from $17.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, February 3rd. Leerink Partners raised shares of Envista from an “underperform” rating to a “market perform” rating and lifted their price objective for the stock from $16.00 to $23.00 in a research note on Thursday, October 31st. Finally, Jefferies Financial Group increased their target price on shares of Envista from $20.00 to $22.00 and gave the company a “hold” rating in a research note on Thursday, January 23rd. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $20.21.

Envista Stock Performance

NYSE:NVST opened at $21.27 on Thursday. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.08 and a quick ratio of 1.77. The company has a market cap of $3.66 billion, a price-to-earnings ratio of -2.74, a PEG ratio of 1.82 and a beta of 1.34. Envista has a 1 year low of $15.15 and a 1 year high of $23.06. The stock’s 50 day simple moving average is $19.96 and its two-hundred day simple moving average is $19.12.

Envista (NYSE:NVST) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. As a group, equities analysts anticipate that Envista will post 0.72 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Iron Triangle Partners LP bought a new position in shares of Envista during the 3rd quarter worth $43,262,000. Point72 Asset Management L.P. bought a new position in Envista during the 3rd quarter worth about $37,559,000. Polar Asset Management Partners Inc. increased its position in Envista by 375.6% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 1,497,250 shares of the company’s stock valued at $29,586,000 after purchasing an additional 1,182,450 shares during the period. Pzena Investment Management LLC bought a new stake in shares of Envista in the 4th quarter valued at about $16,979,000. Finally, Franklin Resources Inc. lifted its position in shares of Envista by 26.5% in the 3rd quarter. Franklin Resources Inc. now owns 3,971,662 shares of the company’s stock worth $78,480,000 after purchasing an additional 830,861 shares during the period.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.